Transferability to clinical practice of the results of controlled clinical trials: The case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting

Annals of Oncology

Volumn 9, Issue 7, 1998, Pages 759-765

  Roila, Kausto ^a  

^a Policlinico Hospital   (Italy)

Author keywords

5 HT3 antagonists; Antiemetics; Chemotherapy induced emesis; Drug utilization; Effectiveness

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; SEROTONIN 3 AGONIST;

ADULT; AGED; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; VOMITING;

EID: 7344220908     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1017132123411     Document Type: Article

References (22)

1. Italian Group for Antiemetic Research. Ondansetron + dexamethasone vs. metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Lancet 1992: 96-9.
2. The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332: 1-5.
3. Kris MG, Gralla RJ, Tyson LB et al. Controlling delayed emesis: Double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7: 108-14.
4. The Italian Group for Antiemetic Research. Ondansetrun versus metoclopramide, both combined with dexamethasone in the prevention of cisplatin-induced delayed emesis. J Clin Oncol 1997; 15: 124-30.
5. Kaizer L, Warr D, Hoskins P et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and cmesis in patients receiving moderately emetogenic chemotherapy: A phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 12: 1050-7.
6. Koo WH, Ang PT. Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 1996; 7: 71-4.
7. Peters II, Kimberly SL, Patel HS et al. Multicenter evaluation of ondansetron use in hospitalized oncology patients. Am J Hosp Pharm 1993; 50: 1164-70.
8. Chapman SM, Pruemer JM. Ondansetron use in a major university teaching hospital. Am J Hosp Pharm 1993; 50: 670-4.
9. Ramm K, De Flon S, Piene H, Trope C. Improving the quality of anti-emetic therapy. Intern J Qual Health Care 1994; 6: 37-40.
10. Vermeulen LC, Matuszewsky KA, Ratko TA et al. Evaluation of ondansetron prescribing in US Academic Medical Centers. Arch Intern Med 1994; 154: 1733-40.
11. Dranitsaris G, Warr D, Poudziunas A. A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron. Support Care Cancer 1995; 3: 183-9.
12. Busch AF, Pearce MJ, Allen B, Begg EJ. Compliance with guidelines results in appropriate ondansetron prescribing at Christchurch Hospital. N Z Med J 1996; 109: 142-4.
13. %)Terrey JP, Casey PA. Granisetron (Kytril): A survey of use in clinical practice in Switzerland. Support Care Cancer 1995; 3: 435-8.
14. Tonato M, Roila F. Antiemetics. In Cavalli F. Hansen HH, Kaye SB (eds): Textbook of Medical Oncology. London: Martin Dunitz Ltd 1997; 363-72.
15. Roila F, Tonato M, Ballatori E, Del Favero A. Comparative studies of various antiemetic regimens. Support Care Cancer 1996; 4: 270-80.
16. Haynes RB, Sackett DL, Guyatt GH et al. Transferring evidence from research into practice: 4. Overcoming barriers to application. ACP J Club 1997; 126 (3, May June): A14-5.
17. Grol R. Personal paper. Beliefs and evidence in changing clinical practice. BMJ 1997; 315: 418-21.
18. Haynes RB, Sackett DL, Muir Gray JA et al. Transferring evidence from research into practice: 1. The role of clinical care research evidence in clinical decisions. ACP J Club 1996; November/December: A14-6.
19. Italian Group for Antiemetic Research. Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. J Clin Oncol 1993; 11: 2396-404.
20. The Italian Group for Antiemetic Research. Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. J Clin Oncol 1995; 13: 2417-26.
21. The Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995; 6: 805-10.
22. Jones AL, Hill AS, Soukop M et al. Comparison of ondansetron vs. dexamethasone in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991; 338: 483-7.